Clinical outcomes in patients with metastatic lung cancer treated with PD-1/PD-L1 inhibitors and thoracic radiotherapy

JAMA Oncology

Volumn 4, Issue 2, 2018, Pages 253-255

  Hwang, William L ^a,b   Niemierko, Andrzej ^b   Hwang, Katie L ^a,b   Hubbeling, Harper ^a,b   Schapira, Emily ^a,b   Gainor, Justin F ^b   Keane, Florence K ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROGRAMMED DEATH 1 LIGAND 1 INHIBITOR; PROGRAMMED DEATH 1 RECEPTOR INHIBITOR; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN TYROSINE KINASE;

ADULT; AGED; ALL CAUSE MORTALITY; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE MUTATION; HUMAN; LETTER; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTATIC LUNG CANCER; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PARTIAL BODY RADIATION; PNEUMONIA; RADIATION DOSE; RADIATION PNEUMONIA; RETROSPECTIVE STUDY; SMALL CELL LUNG CANCER; SURVIVAL TIME; THORACIC RADIOTHERAPY; ADJUVANT RADIOTHERAPY; ANTAGONISTS AND INHIBITORS; CONFORMAL RADIOTHERAPY; IMMUNOLOGY; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; THORAX; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN-TYROSINE KINASES; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; THORAX; TREATMENT OUTCOME;

EID: 85044158484     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.3808     Document Type: Letter

References (6)

1. Reck M, Rodríguez-Abreu D, Robinson AG, et al; KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-1833.
2. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17): 1627-1639.
3. Weber JS, Hodi FS,Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785-792.
4. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-128.
5. PostowMA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925-931.
6. Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895-903.